Madrid, Nov 8 (EFE) .- A candidate for a dengue vaccine prepared by a Japanese laboratory showed an overall efficacy of 80.2% during a test, according to a study published by The New England Journal of Medicine. .
About 20,000 healthy 4- to 16-year-old children from Latin America and Asia participated in a phase III study, which aims to more fully evaluate safety and efficacy in disease prevention and involves more volunteers.
TAK-003 vaccine from the Japanese Takeda laboratory was administered to study participants in Brazil, Colombia, Panama, the Dominican Republic, Nicaragua, the Philippines, Thailand, and Sri Lanka.
Participants who received either the drug or a placebo underwent two doses, with a three-month period between them, and the vaccine was 80.2% effective 12 months after the second.
"It was well tolerated overall, with no significant safety risk so far," the drugmaker said in a statement.
The study showed that the candidate vaccine showed different levels of efficacy depending on the serotype: 73.7% for DENV-1, 97.7% for DENV-2 and 62.6% for DENV-3. For DENV-4, "few cases" were recorded to fully prove efficacy. The safety and effectiveness assessment of participants will continue for a total of four and a half years.
One of the study's authors, Humberto Reynales of the Bogota Medical Research and Care Center, said that "the results of this first analysis are very encouraging, indicating that the vaccine could potentially have important health benefits against dengue."
"It will be important to continue reviewing test results over time to assess the long-term efficacy and safety of the vaccine. If longer follow-up data confirm this initial observation, we are seeing significant progress in the global fight against dengue." commented the expert.
The World Health Organization (WHO) estimates that 390 million dengue infections occur each year, of which 96 million are clinically manifest. EFE